<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02552147</url>
  </required_header>
  <id_info>
    <org_study_id>1502015384</org_study_id>
    <nct_id>NCT02552147</nct_id>
  </id_info>
  <brief_title>Nicotinic Cholinergic Modulation as a Novel Treatment Strategy for Aggression Associated With Autism</brief_title>
  <official_title>Nicotinic Cholinergic Modulation as a Novel Treatment Strategy for Aggression Associated With Autism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Autism Speaks</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Some individuals with autism spectrum disorders (ASD) also demonstrate irritability or
      aggression, which can interfere with functioning. The purpose of this pilot study is to test
      whether transdermal nicotine is effective for irritability and/or aggression in adults with
      ASD using a double-blind, placebo-controlled clinical trial. Subjects will participate in
      three visits. At the first visit, subjects are screened for eligibility and enrolled.
      Baseline measures include rating scales and a frustrative computerized task. They will then
      wear seven days of transdermal nicotine or placebo. Visit two is on day seven and the study
      measures are repeated, vital signs and side effects monitored. Subjects will return for a
      third and final visit on day 21 to repeat the study measures performed during visit two.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Actual">November 17, 2017</completion_date>
  <primary_completion_date type="Actual">November 17, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Aberrant Behavior Checklist Irritability Subscale (ABC-I)</measure>
    <time_frame>Baseline and 7 days.</time_frame>
    <description>Aberrant Behavior Checklist (ABC) measures symptom subscales for individuals with neurodevelopmental disorders. The ABC-irritability subscale measures irritability and related symptoms and the subscale score range is 0 (least symptomatic) to 45 (most symptomatic). The ABC is completed by parents/caregivers.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Social Responsiveness Scale-Adults (SRS-A)</measure>
    <time_frame>Baseline and 7 days.</time_frame>
    <description>The Social Responsiveness Scale (SRS) - 2 quantifies impairments in social behaviors seen in autism spectrum disorder and related conditions and their severity. The version used in this study is completed by parents/caregivers. The raw score range is 0 (unaffected) to &gt; 134 (extremely affected). The ABC is completed by parents/caregivers.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Qualitative Description of Irritability and Aggression Symptoms</measure>
    <time_frame>Baseline and 7 days</time_frame>
    <description>Brief qualitative reports of the patient's subjective experience will be recorded by asking &quot;In what ways did you find the patch helpful or harmful during the past week, if at all?&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Frustration and Irritability Ratings During Frustration-induction Go-NoGo Task</measure>
    <time_frame>Baseline and one week</time_frame>
    <description>Subjects will perform a computerized frustration-induction task and complete a rating scale of irritability and frustration levels.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in State/Trait Anxiety Inventory (STAI) Score</measure>
    <time_frame>Baseline and day 7</time_frame>
    <description>The State-Trait Anxiety Inventory (STAI) is a measure of trait and state anxiety. It ranges from a score of 20 (least affected) to 80 (most affected).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nightly Sleep Quality</measure>
    <time_frame>Day 7</time_frame>
    <description>Caregivers rated nightly sleep quality from 0 (worst) to 10 (best). Average rating for each treatment week is compared.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Autism Spectrum Disorder</condition>
  <condition>Aggression</condition>
  <condition>Irritability</condition>
  <arm_group>
    <arm_group_label>Transdermal nicotine first, placebo last</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subject will receive transdermal nicotine 7 mg daily for 7 days, placebo patch for 7 days, then placebo patch for a final 7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Transdermal placebo first, nicotine last</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subject will receive transdermal placebo daily for 7 days, placebo patch for another 7 days, then transdermal nicotine 7 mg daily for a final 7 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Transdermal nicotine</intervention_name>
    <arm_group_label>Transdermal nicotine first, placebo last</arm_group_label>
    <arm_group_label>Transdermal placebo first, nicotine last</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Transdermal placebo</intervention_name>
    <arm_group_label>Transdermal nicotine first, placebo last</arm_group_label>
    <arm_group_label>Transdermal placebo first, nicotine last</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Age: 18-60

          -  Gender: All

          -  Language: Communicative in English

          -  Participants with a prior diagnosis of DSM-5 ASD at some point in their lifetime OR a
             DSM-4 diagnosis of Autism OR a DSM-4 diagnosis of Asperger's syndrome OR a DSM-4
             diagnosis of Pervasive Developmental Disorder Not Otherwise Specified.

          -  Symptoms of irritability, agitation or aggression as reported by parent and/or
             participant

          -  Aberrant behavior checklist - Irritability Subscale (ABC-I) score of 16 or higher

          -  No changes in psychotropic medications within the past 14 days.

          -  Either lives with a primary caregiver or closely engaged with a primary caregiver who
             interacts with the patient daily

          -  BMI &gt; 17.5 and &lt; 45

        Exclusion criteria:

          -  Age &lt; 18 or &gt; 60

          -  BMI &lt; 17.5 or &gt; 45

          -  Currently using tobacco or any nicotine products (transdermal, gum, e-cigarettes)

          -  Changes in psychotropic medication management within the past 14 days

          -  Previous allergy to transdermal patches

          -  Patients with heart rate &gt; 100 or &lt; 50 or known history of cardiac rhythm
             abnormalities

          -  Systolic blood pressure &gt; 150 or &lt; 95; diastolic blood pressure &gt; 90 or &lt; 50

          -  No symptoms of irritability, agitation, or aggression as reported by parent and/or
             participant

          -  ABC-I score of less than 16

          -  No primary caregiver, or primary caregiver unable to assist with rating scales
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alan S Lewis, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lecturer in psychiatry</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Yale University</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>September 14, 2015</study_first_submitted>
  <study_first_submitted_qc>September 15, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2015</study_first_posted>
  <results_first_submitted>March 9, 2018</results_first_submitted>
  <results_first_submitted_qc>November 23, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">March 14, 2019</results_first_posted>
  <last_update_submitted>November 23, 2018</last_update_submitted>
  <last_update_submitted_qc>November 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 14, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Yale University</investigator_affiliation>
    <investigator_full_name>Alan Lewis</investigator_full_name>
    <investigator_title>Lecturer in psychiatry</investigator_title>
  </responsible_party>
  <keyword>Autism spectrum disorder</keyword>
  <keyword>Aggression</keyword>
  <keyword>Irritability</keyword>
  <keyword>Nicotine</keyword>
  <keyword>Nicotinic acetylcholine receptor</keyword>
  <keyword>Nicotinic agonist</keyword>
  <keyword>Adult autism</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Autistic Disorder</mesh_term>
    <mesh_term>Autism Spectrum Disorder</mesh_term>
    <mesh_term>Aggression</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nicotine</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>November 29, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/47/NCT02552147/ICF_001.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 29, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/47/NCT02552147/Prot_SAP_002.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Transdermal Placebo First, Nicotine Last</title>
          <description>Subject will receive transdermal placebo daily for 7 days, placebo patch for another 7 days, then transdermal nicotine 7 mg daily for a final 7 days.
Transdermal nicotine
Transdermal placebo</description>
        </group>
        <group group_id="P2">
          <title>Transdermal Nicotine First, Placebo Last</title>
          <description>Subject will receive transdermal nicotine 7 mg daily for 7 days, placebo patch for 7 days, then placebo patch for a final 7 days.
Transdermal nicotine
Transdermal placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Intervention (7 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Washout (7 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Second Intervention (7 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>One subject was enrolled and randomized but later determined to be ineligible for the study and not included in the baseline analysis population.</population>
      <group_list>
        <group group_id="B1">
          <title>All Study Participants</title>
          <description>Participants randomized to receive either transdermal nicotine or placebo</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24" spread="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Aberrant Behavior Checklist-Irritability</title>
          <description>Aberrant Behavior Checklist (ABC) measures symptom subscales for individuals with neurodevelopmental disorders. The ABC-irritability subscale measures irritability and related symptoms and the subscale score range is 0 (least symptomatic) to 45 (most symptomatic). The ABC is completed by parents/caregivers.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25" spread="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Aberrant Behavior Checklist-Lethargy/Social withdrawal</title>
          <description>Aberrant Behavior Checklist (ABC) measures symptom subscales for individuals with neurodevelopmental disorders. The ABC-lethargy/social withdrawal subscale measures lethargy/social withdrawal and related symptoms and the subscale score range is 0 (least symptomatic) to 48 (most symptomatic). The ABC is completed by parents/caregivers.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20" spread="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Aberrant Behavior Checklist-Stereotypic behavior</title>
          <description>Aberrant Behavior Checklist (ABC) measures symptom subscales for individuals with neurodevelopmental disorders. The ABC-stereotypic behavior subscale measures stereotypic behaviors and related symptoms and the subscale score range is 0 (least symptomatic) to 21 (most symptomatic). The ABC is completed by parents/caregivers.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9" spread="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Aberrant Behavior Checklist-Hyperactivity</title>
          <description>Aberrant Behavior Checklist (ABC) measures symptom subscales for individuals with neurodevelopmental disorders. The ABC-hyperactivity subscale measures hyperactivity and related symptoms and the subscale score range is 0 (least symptomatic) to 48 (most symptomatic). The ABC is completed by parents/caregivers.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26" spread="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Aberrant Behavior Checklist-Inappropriate speech</title>
          <description>Aberrant Behavior Checklist (ABC) measures symptom subscales for individuals with neurodevelopmental disorders. The ABC-Inappropriate speech subscale measures Inappropriate speech and related symptoms and the subscale score range is 0 (least symptomatic) to 12 (most symptomatic). The ABC is completed by parents/caregivers.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6" spread="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Social Responsiveness Scale-2</title>
          <description>The Social Responsiveness Scale (SRS) - 2 quantifies impairments in social behaviors seen in autism spectrum disorder and related conditions and their severity. The version used in this study is completed by parents/caregivers. The raw score range is 0 (unaffected) to &gt; 134 (extremely affected). The ABC is completed by parents/caregivers.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="177" spread="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number on antipsychotic medication</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Aberrant Behavior Checklist Irritability Subscale (ABC-I)</title>
        <description>Aberrant Behavior Checklist (ABC) measures symptom subscales for individuals with neurodevelopmental disorders. The ABC-irritability subscale measures irritability and related symptoms and the subscale score range is 0 (least symptomatic) to 45 (most symptomatic). The ABC is completed by parents/caregivers.</description>
        <time_frame>Baseline and 7 days.</time_frame>
        <population>All participants who completing all study visits and for which ratings scales were completed in accordance with study protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Nicotine</title>
            <description>Subject receiving transdermal nicotine in either the first or last week of the study and completing all study visits.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subject receiving transdermal placebo in either the first or last week of the study and completing all study visits.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Aberrant Behavior Checklist Irritability Subscale (ABC-I)</title>
          <description>Aberrant Behavior Checklist (ABC) measures symptom subscales for individuals with neurodevelopmental disorders. The ABC-irritability subscale measures irritability and related symptoms and the subscale score range is 0 (least symptomatic) to 45 (most symptomatic). The ABC is completed by parents/caregivers.</description>
          <population>All participants who completing all study visits and for which ratings scales were completed in accordance with study protocol.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12" spread="3"/>
                    <measurement group_id="O2" value="-7" spread="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.44</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>Two-tailed</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Social Responsiveness Scale-Adults (SRS-A)</title>
        <description>The Social Responsiveness Scale (SRS) - 2 quantifies impairments in social behaviors seen in autism spectrum disorder and related conditions and their severity. The version used in this study is completed by parents/caregivers. The raw score range is 0 (unaffected) to &gt; 134 (extremely affected). The ABC is completed by parents/caregivers.</description>
        <time_frame>Baseline and 7 days.</time_frame>
        <population>All participants completing all study visits and for which ratings scales were completed in accordance with study protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Nicotine</title>
            <description>Subject receiving transdermal nicotine in either the first or last week of the study and completing all study visits.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subject receiving transdermal placebo in either the first or last week of the study and completing all study visits.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Social Responsiveness Scale-Adults (SRS-A)</title>
          <description>The Social Responsiveness Scale (SRS) - 2 quantifies impairments in social behaviors seen in autism spectrum disorder and related conditions and their severity. The version used in this study is completed by parents/caregivers. The raw score range is 0 (unaffected) to &gt; 134 (extremely affected). The ABC is completed by parents/caregivers.</description>
          <population>All participants completing all study visits and for which ratings scales were completed in accordance with study protocol.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1" spread="25"/>
                    <measurement group_id="O2" value="-15" spread="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.38</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>Two-tailed</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Qualitative Description of Irritability and Aggression Symptoms</title>
        <description>Brief qualitative reports of the patient's subjective experience will be recorded by asking &quot;In what ways did you find the patch helpful or harmful during the past week, if at all?&quot;.</description>
        <time_frame>Baseline and 7 days</time_frame>
        <population>Data were not collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Nicotine</title>
            <description>Subject receiving transdermal nicotine in either the first or last week of the study and completing all study visits.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subject receiving transdermal placebo in either the first or last week of the study and completing all study visits.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Qualitative Description of Irritability and Aggression Symptoms</title>
          <description>Brief qualitative reports of the patient's subjective experience will be recorded by asking &quot;In what ways did you find the patch helpful or harmful during the past week, if at all?&quot;.</description>
          <population>Data were not collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Frustration and Irritability Ratings During Frustration-induction Go-NoGo Task</title>
        <description>Subjects will perform a computerized frustration-induction task and complete a rating scale of irritability and frustration levels.</description>
        <time_frame>Baseline and one week</time_frame>
        <population>Data were not collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Nicotine</title>
            <description>Subject receiving transdermal nicotine in either the first or last week of the study and completing all study visits.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subject receiving transdermal placebo in either the first or last week of the study and completing all study visits.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Frustration and Irritability Ratings During Frustration-induction Go-NoGo Task</title>
          <description>Subjects will perform a computerized frustration-induction task and complete a rating scale of irritability and frustration levels.</description>
          <population>Data were not collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in State/Trait Anxiety Inventory (STAI) Score</title>
        <description>The State-Trait Anxiety Inventory (STAI) is a measure of trait and state anxiety. It ranges from a score of 20 (least affected) to 80 (most affected).</description>
        <time_frame>Baseline and day 7</time_frame>
        <population>Data were not collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Nicotine</title>
            <description>Subject receiving transdermal nicotine in either the first or last week of the study and completing all study visits.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subject receiving transdermal placebo in either the first or last week of the study and completing all study visits.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in State/Trait Anxiety Inventory (STAI) Score</title>
          <description>The State-Trait Anxiety Inventory (STAI) is a measure of trait and state anxiety. It ranges from a score of 20 (least affected) to 80 (most affected).</description>
          <population>Data were not collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Nightly Sleep Quality</title>
        <description>Caregivers rated nightly sleep quality from 0 (worst) to 10 (best). Average rating for each treatment week is compared.</description>
        <time_frame>Day 7</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Nicotine</title>
            <description>Subject receiving transdermal nicotine in either the first or last week of the study and completing all study visits.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subject receiving transdermal placebo in either the first or last week of the study and completing all study visits.</description>
          </group>
        </group_list>
        <measure>
          <title>Nightly Sleep Quality</title>
          <description>Caregivers rated nightly sleep quality from 0 (worst) to 10 (best). Average rating for each treatment week is compared.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10" spread="0.2"/>
                    <measurement group_id="O2" value="9" spread="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.13</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>Two-tailed</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Aberrant Behavior Checklist - Lethargy/Social Withdrawal Subscale Change From Baseline</title>
        <description>Aberrant Behavior Checklist (ABC) measures symptom subscales for individuals with neurodevelopmental disorders. The ABC-lethargy/social withdrawal subscale measures lethargy/social withdrawal and related symptoms and the subscale score range is 0 (least symptomatic) to 48 (most symptomatic). The ABC is completed by parents/caregivers.</description>
        <time_frame>Baseline and 7 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Nicotine</title>
            <description>Subject receiving transdermal nicotine in either the first or last week of the study and completing all study visits.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subject receiving transdermal placebo in either the first or last week of the study and completing all study visits.</description>
          </group>
        </group_list>
        <measure>
          <title>Aberrant Behavior Checklist - Lethargy/Social Withdrawal Subscale Change From Baseline</title>
          <description>Aberrant Behavior Checklist (ABC) measures symptom subscales for individuals with neurodevelopmental disorders. The ABC-lethargy/social withdrawal subscale measures lethargy/social withdrawal and related symptoms and the subscale score range is 0 (least symptomatic) to 48 (most symptomatic). The ABC is completed by parents/caregivers.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2" spread="3"/>
                    <measurement group_id="O2" value="-7" spread="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.13</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>Two-tailed</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Aberrant Behavior Checklist - Stereotypic Behavior Subscale Change From Baseline</title>
        <description>Aberrant Behavior Checklist (ABC) measures symptom subscales for individuals with neurodevelopmental disorders. The ABC-stereotypic behavior subscale measures stereotypic behaviors and related symptoms and the subscale score range is 0 (least symptomatic) to 21 (most symptomatic). The ABC is completed by parents/caregivers.</description>
        <time_frame>Baseline and 7 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Nicotine</title>
            <description>Subject receiving transdermal nicotine in either the first or last week of the study and completing all study visits.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subject receiving transdermal placebo in either the first or last week of the study and completing all study visits.</description>
          </group>
        </group_list>
        <measure>
          <title>Aberrant Behavior Checklist - Stereotypic Behavior Subscale Change From Baseline</title>
          <description>Aberrant Behavior Checklist (ABC) measures symptom subscales for individuals with neurodevelopmental disorders. The ABC-stereotypic behavior subscale measures stereotypic behaviors and related symptoms and the subscale score range is 0 (least symptomatic) to 21 (most symptomatic). The ABC is completed by parents/caregivers.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2" spread="3"/>
                    <measurement group_id="O2" value="-4" spread="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.50</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>Two-tailed</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Aberrant Behavior Checklist - Hyperactivity Subscale Change From Baseline</title>
        <description>Aberrant Behavior Checklist (ABC) measures symptom subscales for individuals with neurodevelopmental disorders. The ABC-hyperactivity subscale measures hyperactivity and related symptoms and the subscale score range is 0 (least symptomatic) to 48 (most symptomatic). The ABC is completed by parents/caregivers.</description>
        <time_frame>Baseline and 7 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Nicotine</title>
            <description>Subject receiving transdermal nicotine in either the first or last week of the study and completing all study visits.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subject receiving transdermal placebo in either the first or last week of the study and completing all study visits.</description>
          </group>
        </group_list>
        <measure>
          <title>Aberrant Behavior Checklist - Hyperactivity Subscale Change From Baseline</title>
          <description>Aberrant Behavior Checklist (ABC) measures symptom subscales for individuals with neurodevelopmental disorders. The ABC-hyperactivity subscale measures hyperactivity and related symptoms and the subscale score range is 0 (least symptomatic) to 48 (most symptomatic). The ABC is completed by parents/caregivers.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7" spread="6"/>
                    <measurement group_id="O2" value="-6" spread="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>1.0</p_value>
            <p_value_desc>P value was calculated to &gt;0.99 and thus rounded to 1.0.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>Two-tailed</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Aberrant Behavior Checklist - Inappropriate Speech Subscale Change From Baseline</title>
        <description>Aberrant Behavior Checklist (ABC) measures symptom subscales for individuals with neurodevelopmental disorders. The ABC-Inappropriate speech subscale measures Inappropriate speech and related symptoms and the subscale score range is 0 (least symptomatic) to 12 (most symptomatic). The ABC is completed by parents/caregivers.</description>
        <time_frame>Baseline and 7 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Nicotine</title>
            <description>Subject receiving transdermal nicotine in either the first or last week of the study and completing all study visits.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subject receiving transdermal placebo in either the first or last week of the study and completing all study visits.</description>
          </group>
        </group_list>
        <measure>
          <title>Aberrant Behavior Checklist - Inappropriate Speech Subscale Change From Baseline</title>
          <description>Aberrant Behavior Checklist (ABC) measures symptom subscales for individuals with neurodevelopmental disorders. The ABC-Inappropriate speech subscale measures Inappropriate speech and related symptoms and the subscale score range is 0 (least symptomatic) to 12 (most symptomatic). The ABC is completed by parents/caregivers.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1" spread="2"/>
                    <measurement group_id="O2" value="0.2" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.25</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>Two-tailed</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Global Aggressive Behavior Improvement</title>
        <description>Caregivers asked which treatment week showed the greatest improvement in aggressive or irritable behavior</description>
        <time_frame>Baseline and 7 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Nicotine</title>
            <description>Subject receiving transdermal nicotine in either the first or last week of the study and completing all study visits.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subject receiving transdermal placebo in either the first or last week of the study and completing all study visits.</description>
          </group>
        </group_list>
        <measure>
          <title>Global Aggressive Behavior Improvement</title>
          <description>Caregivers asked which treatment week showed the greatest improvement in aggressive or irritable behavior</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.69</p_value>
            <method>Binomial test</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Duration of trial (3 weeks).</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Nicotine</title>
          <description>Subject receiving transdermal nicotine in either the first or last week of the study and completing all study visits.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Subject receiving transdermal placebo in either the first or last week of the study and completing all study visits.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Nightmare</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Unable to recruit the pre-specified number of subjects; Subjects were unable to reliably complete personal ratings (STAI and STAXI) and were unable to reliably complete the frustrative computer task.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Alan Lewis, MD, PhD</name_or_title>
      <organization>Vanderbilt University Medical Center</organization>
      <phone>(615) 936-4997</phone>
      <email>alan.s.lewis@vumc.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

